Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324007 | 0.85 | CA1 (0.40) | KIF11EPHX2PDE2AKCNA3KDM4E | |
| SCHEMBL13561307 | 0.83 | PON1 (0.41) | KIF11KCNA3KDM4EALDH1A1MEN1 | |
| SCHEMBL6672301 | 0.78 | KCNA3 (0.35) | EPHX2KCNA3KDM4EALDH1A1MAOB | |
| SCHEMBL20274083 | 0.78 | EPHX2 (0.41) | KIF11EPHX2PDE2AALDH1A1MAOB | |
| SCHEMBL21116465 | 0.77 | TP53 (0.46) | KIF11EPHX2MAOBMAPTTP53 | |
| SCHEMBL15898927 | 0.75 | PDE2A (0.41) | KIF11EPHX2PDE2AMAOBMAPT | |
| SCHEMBL21116466 | 0.75 | TP53 (0.46) | EPHX2MAOBMAPTTP53SMN1; SMN2 | |
| SCHEMBL18014739 | 0.75 | TP53 (0.41) | KIF11EPHX2MAOBMAPTTP53 | |
| SCHEMBL18015849 | 0.75 | MTNR1A (0.45) | KDM4EALDH1A1MAPTTP53SMN1; SMN2 | |
| SCHEMBL31231895 | 0.75 | PTPN1 (0.50) | KCNA3KDM4EALDH1A1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-18 | — | — | US | disclosed |
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| EP-3052495-B1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3052495-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
| WO-2015049616-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1373259-B1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1373259-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2003-08-28 | — | — | US | disclosed |
| US-6579879-B2 | Pyridazinone aldose reductase inhibitors | PFIZER INC | 2003-06-17 | — | — | US | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002079198-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | KIF11 4297/4885EPHX2 1764/4885PDE2A 1036/4885 |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | KIF11 4391/4885EPHX2 2393/4885PDE2A 1406/4885 |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | KIF11 4539/4885EPHX2 1322/4885PDE2A 1184/4885 |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | KIF11 4331/4885EPHX2 1152/4885PDE2A 79/4885 |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, AKR1B1, AKR1D1 | KIF11 4364/4885EPHX2 1231/4885PDE2A 93/4885 |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | KIF11 4835/4885EPHX2 555/4885PDE2A 369/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | KIF11 4817/4885EPHX2 510/4885PDE2A 363/4885 |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | KIF11 4297/4885EPHX2 1764/4885PDE2A 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.